This electron microscope image provided by the National Institutes of Health shows human respiratory syncytial virus virions, colorized blue, and anti-RSV F protein/gold antibodies, colorized yellow, shedding from the surface of human lung cells.
RSV, or respiratory syncytial virus, is a common cause of cold-like symptoms but it can be dangerous for infants and the elderly. Instead, they voted that people 75 and older should get the shots and that those 60 to 74 should do so only if they are higher risk for severe disease. The panel also declined to endorse giving the GSK vaccine to people in their 50s, even though the FDA this month licensed the company's shot for that age group.Panel members said data has demonstrated that the shots make sense for all people 75 and older, because they are at higher risk for severe RSV cases.
Underlying the panel's hesitancy are reports of a nervous system disorder, Guillain-Barre syndrome. Though rare, there have been a higher-than-expected number of Guillain-Barre cases among RSV vaccine recipients, particularly in those who got the Pfizer shot. Ontario is the only province offering the new RSV vaccine to eligible groups for free. Here's what to know
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: YahooFinanceCA - 🏆 47. / 63 Read more »